Top Message
Co-creation
Building the future of healthcare and new value through co-creation and innovation
I am pleased to announce my appointment as Chairman of the Japan Pharmaceutical Manufacturers Association (JPMA). At the outset, I would like to pay tribute to the tremendous contributions you have made to the development of Japan's pharmaceutical industry and express my deep appreciation for the opportunity you have given me to take on this important responsibility.
The mission of pharmaceutical companies is to utilize cutting-edge science and technology to develop new drugs that are more effective and safe, and to deliver them quickly and consistently to patients in need. The creation of innovative drugs not only provides new means of treatment, but also contributes to the optimization of healthcare costs and the improvement of patients' quality of life (QOL). In recent years, a number of innovative new drugs have been introduced in the fields of oncology, rare diseases, and dementia, and our goal is to further accelerate the research and development of these drugs.
Japan Pharmaceutical Manufacturers Association
Asuka Miyabashira, Chairman
The social value of pharmaceuticals and their potential as an industry are also considered important in the national growth strategy. In addition to revitalizing the domestic market, spreading Japan's advanced drug discovery technologies throughout the world through overseas expansion will contribute to the sustainable development of the economy as a whole. With the growth of emerging markets, particularly in Asia, we believe that it will become even more significant for Japanese pharmaceutical companies to increase their presence in these regions.
At the core of the Pharmaceutical Manufacturers Association of Japan's industrial vision is the concept of "co-creation" from the patient's perspective, which aims to realize "drug discovery with patient and citizen participation" and, beyond drug discovery, a sustainable society in which all citizens can live long and healthy lives. To this end, it is also essential to promote the digital transformation of healthcare through the utilization of medical data and AI. We will lead Japan's healthcare in a better direction by creating new value for society through dialogue with a diverse range of stakeholders, including patients, government, medical professionals, and academia.
Our ultimate goal as a pharmaceutical company is to realize a society in which all people can lead healthy and fulfilling lives. We will further promote innovation in the pharmaceutical industry toward the establishment of a sustainable social security system and contribute to the development of Japan's healthcare and economy.
Asuka Miyabashira, Chairman, Japan Pharmaceutical Manufacturers Association, Inc.